Second registration trial of tenapanor to treat hyperphosphatemia
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Tenapanor (Primary)
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Ardelyx
- 21 Nov 2017 According to an Ardelyx media release, based on the feedback recently received, the company will add an active control arm to the study for safety assessment only, consistent with the design of registration studies for phosphate binders. Ardelyx is updating the study protocol and preparing to begin enrollment.
- 09 Aug 2017 According to an Ardelyx media release, the company expects to begin patient enrollment by October of 2017.
- 17 Feb 2017 According to an Ardelyx media release, company is planning to initiate this trial by mid-year 2017.